1. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006;28:112–125.
2. Korea centers for disease control and prevention: the fourth Korea National Health and Nutrition Examination Survey 2007. 2008.
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–686.
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73.
5. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001–1010.
6. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72–79.
7. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503–1514.
8. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714–1722.
9. The Korean Association for the Study of the Liver (KASL). KASL Clinical Practice Guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2012;18:109–162.
10. Song BC, Chae HB, Kim YN, Lee BS, Cho YK. Pretreatment levels of HBV DNA and early virological response during entecavir therapy predicts HBeAg loss in HBeAgpositive chronic hepatitis B patients. Korean J Hepatol 2009;15(Supp1 3):S42.
11. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011–1020.
13. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B: the Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295–301.
15. Tseng TC, Liu CJ, Wang CC, et al. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int 2008;28:1034–1041.
16. Westland C, Delaney W 4th, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003;125:107–116.
17. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283–290.
18. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130–141.
19. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121–129.
20. Zarski JP, Marcellin P, Cohard M, Lutz JM, Bouche C, Rais A. Comparison of anti-HBe-positive and HBe-antigenpositive chronic hepatitis B in France: French Multicentre Group. J Hepatol 1994;20:636–640.
22. Degertekin B, Lok AS. Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used? J Hepatol 2008;48:892–894.
23. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254–265.
24. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960–967.
25. Adams LA, Knuiman MW, Divitini ML, Olynyk JK. Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption. J Gastroenterol Hepatol 2008;23(7 Pt 1):1089–1093.